Phase 3 study for people with Melanoma

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Replimune, Inc.
Registry number NCT06581406
Started 17 December 2024 Today 16 October 2026 Estimated completion 1 January 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Melanoma Institute Australia Wollstonecraft NSW Recruiting
Peter MacCallum Cancer Centre Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age child, adult, older adult
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 280

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Patients who are 18 years of age or older at the time of signed informed consent.

* Patients with confirmed diagnosis of metastatic Uveal melanoma not amenable to surgical resection.

* Has at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for a lymph node \[LN\]) that is amenable to serial RP2 injections.

* Must be willing to provide tumor biopsy samples.

* LDH ≤ 2 × upper limit of normal (ULN).

* Has adequate hematologic, hepatic and renal function

* Prothrombin time (PT) ≤ 1.5 × ULN (or international normalization ratio \[INR\] ≤ 1.3) and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.

* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

* Life expectancy of \> 6 months as estimated by the Investigator.

Key Exclusion Criteria:

* Any exposure to immune checkpoint inhibitor (ICIs) since the time of first being diagnosed with uveal melanoma.

* Known acute or chronic Hepatitis B or C infection or human immunodeficiency virus (HIV) infection or any other uncontrolled infection.

* Current active significant herpetic infections or prior complications of HSV-1 infection.

* Any central nervous system (CNS) involvement of melanoma, including carcinomatous meningitis.

* Major surgery ≤ 2 weeks prior to the first dose of study intervention.

* Any bleeding, thrombotic and/or other event that places the patient at an unacceptable risk of complications of intratumoral therapy.

* Active, known, or suspected autoimmune disease requiring systemic treatment.

* Prior treatment with an oncolytic virus.

* Requires intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir).

* Systemic anticancer therapy or prior radiotherapy within 2 weeks of the first dose.

* Has received Investigation agent within 4 weeks or 5 half-lives (whichever longer) prior to the first dose.

* Conditions requiring treatment with immunosuppressive doses (\> 10 mg per day of prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days after enrollment.

Additional inclusion/ exclusion criteria are outlined in the study protocol

Dates on the record

Started 17 December 2024
Estimated completion 1 January 2030
Registry last updated 2 April 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 2 April 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.